Floatz logo

(+)-VINCRISTINE

Hormone-resistant Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversitySmall moleculePhase 3Dormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Hormone-resistant Prostate Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
Roswell Park Cancer Institute
Phase 3BB
PREDNISONE TABLETS
University of California, Davis
Phase 3BB
Abiraterone Acetate
Alliance for Clinical Trials in Oncology
Phase 3BB
Rebimastat
National Cancer Institute (NCI)
Phase 2B
Eloxatin
University of Southern California
Phase 2B

View all 27 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →